Insight

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Photo of Karen Bedirian from immonc.org

Feb 14, 2024, 13:40

Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer

Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn:

“Happy to share that IMMONC received regulatory approval to conduct a clinical trial of BAL+BOT among patients with metastatic non-small cell lung cancer.
We received the approval of the Center of Drug and Medical Technology in just 30 working days and the approval of the MoH Ethics Committee in just 9 working days.

Grateful for the team’s efforts. Immune Oncology Research Institute
Thank you Agenus for the continued support.”

Source: Karen Bedirian/LinkedIn

Agenus BAL+BOT Balstilimab botensilimab cancer IMMONC Immune Oncology Research Institute Karen Bedirian metastatic non-small cell lung cancer OncoDaily Oncology

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Special Coverage